Risk factors
Voyager Therapeutics (VYGR) risk factors
Item 1A of every Voyager Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors75 risks15 new7 dropped18 reworded
Voyager Therapeutics faces new risks from government shutdowns disrupting FDA reviews, international tariff policies, and strict foreign anti-bribery and data privacy laws. Clinical programs like VY1706 and VY7523 remain in early development stages with historical collaboration terminations.
Filed Mar 09, 2026 - FY2024 10-K risk factors67 risks
Voyager Therapeutics faces substantial early-stage biotechnology risks, including no product revenues, heavy reliance on capital raises, and complex gene therapy manufacturing.
Filed Mar 11, 2025